Abstract: The present invention relates to methods for the production of ?-3 and/or ?-6 fatty acids in oleaginous yeast. Thus, desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to ?-linolenic acid (GLA); ?-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-?-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to arachidonic acid (ARA); ETA to eicosapentaenoic acid (EPA); DGLA to ETA; EPA to docosapentaenoic acid (DPA); and ARA to EPA have been introduced into the genome of Yarrowia for synthesis of ARA and EPA.

Abstract: The present invention provides a complex of the transcription coupling factor of any of ARNT 1 to 3 and the transcription regulatory factor comprising any of the amino acid sequence from the amino acid sequence group comprising for example the amino acid sequences represented by SEQ ID Nos.1 to 3, which is a transcription activating complex having an ability of binding to a DNA region (5?-ACGTG-3?, SEQ ID No.16) to which a transcription inhibiting complex of the transcription coupling factor and a Sim2 as a transcription regulatory factor can be bound and having an ability of promoting the transcription of a gene located downstream of the DNA region.

Abstract: Murine leukemia virus (MLV) and lentivirus vectors have been used previously to deliver genes to hematopoietic stem cells (HSCs) in human gene therapy trials. However, these vectors integrate randomly into the host genome, leading to disruption or inactivation of vital host genes. The present invention discloses a novel lentiviral vector system that overcomes this problem by integrating into a host genome in a site-specific manner.

Abstract: The invention provides a method of mapping DNA-protein interactions within a genome by fixing living cells to cross-link DNA and proteins, lysing the cells, and isolating chromatin by immunoprecipitation. DNA is purified and a SAGE protocol is performed on the purified DNA to produce GMAT-tag sequences, which are compared to a genomic sequence of the living cells to map DNA-protein interactions. The invention further provides a method of identifying an active chromatin domain and a method of identifying aberrant chromatin acetylation, wherein chromatin immunoprecipitation is performed using an antibody recognizing acetylated histone protein.

Abstract: Disclosed are mutated genes for green fluorescence proteins and enhanced inserted YFPs expressed therefrom. The mutant proteins not only maintain their fluorescence even at 37° C., but also exhibit about 20 times stronger fluorescence intensities in comparison to the conventional fluorescence proteins. Accordingly, the mutant fluorescence proteins of the present invention can be used as biosensors for detecting and analyzing the bioactivities of desired materials.

Abstract: Chemically inducible promoters are described that may be used to transform plants, including tobacco and lettuce, with genes which are easily regulatable by adding the plants or plant cells to a medium containing an inducer of the promoter or by removing the plants or plant cells from such medium. The promoters described are ones that are inducible by a glucocorticoid or estrogen which is not endogenous to plants. Such promoters may be used with a variety of genes such as ipt, CKI1, or knotted1, to induce shoot formation in the presence of an appropriate inducer. The promoters may be used with genes which induce somatic embryos such as Lec1 or SERK to prepare somatic embryos which can be grown into seedlings and then into plants. The promoter may also be used with antibiotic or herbicide resistance genes which are then regulatable by the presence or absence of inducer rather than being constitutive. Other examples of genes which may be placed under the control of the inducible promoter are also presented.

Abstract: A method of inducing liver regeneration in a damaged liver tissue region of an individual is provided. The method including the step of providing at least two distinct growth factors to the damaged liver tissue region of the individual, at least one of the at least two distinct growth factors being an angiogenic factor.

Abstract: The present invention is directed to a method for producing commercial quantities of baculovirus using a combination of methods involving producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture. A two step method was developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.

Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Abstract: A novel DNA is provided which encodes an enzyme having phytase activity isolated from Trichoderma. Also provided for is a method of isolating DNA encoding an enzyme having phytase activity from organisms which possess such DNA, transformation of the DNA into a suitable host organism, expression of the transformed DNA and the use of the expressed phytase protein in feed as a supplement.

Abstract: The present invention relates to fatty acid desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to ?-linolenic acid (GLA); ?-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-?-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to ETA; eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA); and arachidonic acid (ARA) to EPA. Nucleic acid sequences encoding codon-optimized desaturases and elongases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the codon-optimized desaturase or elongases, and recombinant host microorganisms expressing increased levels of desaturase or elongase are described.

Abstract: The present invention provides an RNA polymerase III promoter characterized in that a part of its sequence is substituted with a sequence capable of undergoing specific DNA recombination by Cre recombinase in such a manner functions of PSE and a TATA box are not impaired. This RNA polymerase III promoter can be used in a RNAi induction method with the condition that RNAi molecules to be used in analyzing gene function can be induced at an arbitrary point of time or only in a specific tissue (organ).

Abstract: The present invention provides isolated nucleic acids and proteins that are new and distinct members of the bHLH-PAS superfamily of transcription regulators. These “MOPs” (members of PAS) are useful in a variety of research, diagnostic and therapeutic applications. Several of the MOPs of the present invention are ?-class hypoxia-inducible factors. Several other of the MOPs of the invention are involved in circadian signal transduction.

Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.

Abstract: The invention relates to a VAC-BAC shuttle vector system for creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome.

Abstract: Provided are novel vectors and viral vectors capable of expressing exogenous gene or exogenous nucleic acid sequences in a target cell of interest, such as T cells, bone marrow cells, epithelial cells, liver cells and the like. The nucleic acid components of the vectors may include one or more native promoter/enhancer regions having modified sequence segments, one or more non-native promoter/enhancer or non-native promoter's gene or gene segment, and a native viral vector terminator or processing signal or segment thereof. The viral vectors comprise a virus or viral portion having on the surfaces or envelopes adsorption components, one for a packaging cell line and the other for delivery to a target cell. Packaging cell lines for propagating the vectors and viral vectors are also provided, as are novel processes for propagating any of the disclosed vectors or viral vectors.

Abstract: A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the (5?) inverted terminal repeat, the left terminus spans the E4 region and the (3?) inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.

Abstract: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor.

Abstract: The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles.